InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (2 ops.)
Explore the complete record of transactions filed by Johnson Wendy S., Directrice du Développement. Director active across 2 companies, notably Reneo Pharmaceuticals, Inc.. In total, 6 disclosures have been logged. Total volume traded: €1.6m. The latest transaction was disclosed on 3 September 2021 — Acquisition. Regulator: SEC (Form 4). The full history is free.
Declarations6 total
€11,8051,000 shares@ €11.80480.013% mcap100.0% of flow
Common Stock
SEC:0001274737-21-000101·
Ideal exit: 31 May 2022 (T+270)
€11,8051,000 shares@ €11.80480.013% mcap50.0% of flow
Common Stock
SEC:0001274737-21-000101:0·
Ideal exit: 31 May 2022 (T+270)
€802,610111,736 shares@ €7.183181.2% of flow
Common Stock
SEC:0001209191-21-046802·
€802,610111,736 shares@ €7.183140.6% of flow
Common Stock
SEC:0001209191-21-046802:0·
€185,787111,736 shares@ €1.662718.8% of flow
Common Stock
SEC:0001209191-21-046254·
€185,787111,736 shares@ €1.66279.4% of flow
Common Stock
SEC:0001209191-21-046254:0·
6 of 6 declarations
About Johnson Wendy S.
Johnson Wendy S. is the Chief Development Officer and a Board Member at Reneo Pharmaceuticals, Inc. and EXAGEN INC. She is responsible for leading strategic development initiatives and implementing key projects for the company. Her role involves collaborating with various teams to ensure the success of development programs. She plays a crucial role in shaping the future direction of both companies.
